SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: Miguel M. de la O who wrote (312)10/22/1998 4:22:00 PM
From: All Mtn Ski  Respond to of 548
 
Perhaps, but Alliance is one of the few blood-substitute stocks left with a potential product, so maybe awareness of this is spreading. I would like to see the 10's again!

Tom



To: Miguel M. de la O who wrote (312)10/24/1998 1:34:00 AM
From: Alok Sinha  Read Replies (1) | Respond to of 548
 
I doubt any deal with Oxygent is in the works. The move and volume in the stock may be related to some announcement forthcoming regarding beginning of Phase III trials for Oxygent and pivtal study (phase II/III) for Liquivent. Aliance's intent was to begin these studies before the end of the year afer finalizing the protocol with the FDA.

Regards

Alok


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News